Systemic exposure of everolimus after stent implantation: A pharmacokinetic study

American Heart Journal

Volumn 156, Issue 4, 2008, Pages 751.e1-751.e7

  Wiemer, Marcus ^a,j   Seth, Ashok ^a,b   Chandra, Praveen ^a,b   Neuzner, Jörg ^a,c   Richardt, Gert ^a,d   Piek, Jan J ^a,e   Desaga, Martin ^a,f   Macaya, Carlos ^a,g   Bol, Cornelis J ^a,h   Miquel Hebert, Karine ^a,i   De Roeck, Karolien ^a,i   Serruys, Patrick W ^a,j  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Max Devki Devi Heart and Vascular Institute   (India)

^c Herzzentrum   (Germany)

^d Segeberger Kliniken   (Germany)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f Amper Kliniken AG   (Germany)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h Kinesis Pharma   (Netherlands)

ⁱ Abbott Vascular International BVBA   (Belgium)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY STENT; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELUTING STENT; DRUG EXPOSURE; DRUG RELEASE; DRUG SAFETY; FEMALE; HEART DEATH; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; MALE; MASS SPECTROMETRY; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SYSTEMIC DISEASE; THROMBOSIS; VALIDATION PROCESS;

EID: 53149149858     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.07.005     Document Type: Article

References (21)

1. Serruys P.W., Kutryk M.J., and Ong A.T. Coronary-artery stents. N Engl J Med 354 (2006) 483-495
2. Camenzind E., Steg G., and Wijns W. A cause of concern. Circulation 115 (2007) 1440-1455
3. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
4. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a metaanalysis. Eur Heart J 27 (2006) 2784-2814
5. Vetrovec G.W., Rizik D., Willard C., Snead D., Piotrovski V., Kopia G., et al. Sirolimus PK Trial: a pharmacokinetic study of the sirolimus-eluting BX Velocity stent in patients with de novo coronary lesions. Cath Cardiovasc Interv 67 (2006) 32-37
6. Chapman T.M., and Perry C.M. Everolimus. Drugs 64 (2004) 861-872
7. Costa R.A., Lansky A.J., Mintz G.S., et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 95 (2005) 113-116
8. Grube E., Sonoda S., Ikeno F., et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109 (2004) 2168-2171
9. Tsuchiya Y., Lansky A.J., Costa R.A., et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 98 (2006) 464-469
10. Grube E. FUTURE II: multicenter evaluation of the bioabsorbable polymer-based everolimus-eluting stent TCT 2003 (2003) [Washington, DC]
11. Serruys P., AT O., Piek J.J., et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. Euro Intervention 1 (2005) 58-65
12. Tsuchida K., Piek J.J., Neumann F.J., et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). Euro Intervention 1 (2005) 266-272
13. Serruys P.W., Ruygrok P., Neuzner J., et al. Randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Euro Intervention 2 (2006) 286-294
14. Kovarik J.M., Eisen H., Dorent R., et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant 22 (2003) 1117-1125
15. Starling R.C., Hare J.M., Hauptmann P., et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 4 (2004) 2126-2131
16. Kovarik J.M., Kaplan B., and Tedesco Silva H. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 73 (2002) 920-925
17. Kovarik J.M., Snell G.I., Valentine V., et al. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant 25 (2006) 440-446
18. Baldelli S., Murgia S., Merlini S., et al. High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. J Chromatogr B 816 (2005) 99-105
19. Mabasa V.H., and Ensom M.H. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit 27 (2005) 666-676
20. Kovarik J.M., Tedesco H., Pascual J., et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 26 (2004) 499-505
21. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivate: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36-42